PL1725553T3 - Pochodne tetrahydropirydoindolu - Google Patents

Pochodne tetrahydropirydoindolu

Info

Publication number: PL1725553T3
Authority: PL; Poland
Prior art keywords: tetrahydropyridoindole derivatives; tetrahydropyridoindole; derivatives
Prior art date: 2004-03-11

Application number

PL05715779T

Other languages

English (en)

Inventor

Heinz Fretz

Anja Fecher

Kurt Hilpert

Markus Riederer

Original Assignee

Idorsia Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-11

Filing date

2005-03-07

Publication date

2008-10-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34961211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1725553(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-03-07 Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd

2008-10-31 Publication of PL1725553T3 publication Critical patent/PL1725553T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Otolaryngology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Indole Compounds (AREA)

PL05715779T 2004-03-11 2005-03-07 Pochodne tetrahydropirydoindolu PL1725553T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP2004002493		2004-03-11
PCT/EP2005/002362 WO2005095397A1 (en)	2004-03-11	2005-03-07	Tetrahydropyridoindole derivatives
EP05715779A EP1725553B1 (en)	2004-03-11	2005-03-07	Tetrahydropyridoindole derivatives

Publications (1)

Publication Number	Publication Date
PL1725553T3 true PL1725553T3 (pl)	2008-10-31

Family

ID=34961211

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL05715779T PL1725553T3 (pl)	2004-03-11	2005-03-07	Pochodne tetrahydropirydoindolu

Country Status (24)

Country	Link
US (2)	US7714132B2 (pl)
EP (1)	EP1725553B1 (pl)
JP (1)	JP4051398B2 (pl)
KR (1)	KR100808742B1 (pl)
CN (1)	CN1930162B (pl)
AR (1)	AR047928A1 (pl)
AT (1)	ATE394399T1 (pl)
AU (1)	AU2005229356B2 (pl)
BR (1)	BRPI0508540B8 (pl)
CA (1)	CA2558509C (pl)
DE (1)	DE602005006539D1 (pl)
DK (1)	DK1725553T3 (pl)
ES (1)	ES2304010T3 (pl)
IL (1)	IL177968A0 (pl)
MY (1)	MY143795A (pl)
NO (1)	NO337996B1 (pl)
NZ (1)	NZ550365A (pl)
PL (1)	PL1725553T3 (pl)
PT (1)	PT1725553E (pl)
RU (1)	RU2387652C2 (pl)
SI (1)	SI1725553T1 (pl)
TW (1)	TWI369356B (pl)
WO (1)	WO2005095397A1 (pl)
ZA (1)	ZA200608446B (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE518834T1 (de)	2004-12-27	2011-08-15	Actelion Pharmaceuticals Ltd	2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
RU2303597C1 (ru) *	2006-05-12	2007-07-27	Иващенко Андрей Александрович	Фармацевтическая композиция, способы ее получения и применения
US20150072963A1 (en) *	2006-06-16	2015-03-12	The Trustees Of The University Of Pennsylvania	Compositions and methods for regulating hair growth
WO2007149312A2 (en)	2006-06-16	2007-12-27	The Trustees Of The University Of Pennsylvania	Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph
JP5220013B2 (ja) *	2006-08-07	2013-06-26	アクテリオンファーマシューティカルズリミテッド	（３−アミノ−１，２，３，４−テトラヒドロ−９ｈ−カルバゾール−９−イル）−酢酸誘導体
EP2099444A4 (en)	2006-12-14	2012-11-07	Nps Pharma Inc	USE OF D-SERIN DERIVATIVES FOR THE TREATMENT OF ANTIBODIES
EA200970841A1 (ru)	2007-03-09	2010-04-30	ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи	Фармацевтическое применение замещенных амидов
RU2338745C1 (ru) *	2007-03-21	2008-11-20	Андрей Александрович Иващенко	ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
EP2197438B1 (en) *	2007-10-10	2015-07-15	Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.	Heterocyclic compounds as crth2 receptor antagonists
JP5666036B2 (ja) *	2008-01-25	2015-02-04	メディベイションテクノロジーズ，インコーポレイテッド	新規２，３，４，５−テトラヒドロ−１Ｈ−ピリド［４，３−ｂ］インドール化合物およびその使用方法
RU2544856C2 (ru) *	2008-01-25	2015-03-20	Сергей Олегович Бачурин	НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US20110112134A1 (en) *	2008-05-16	2011-05-12	Amira Pharmaceuticals, Inc.	Tricyclic Antagonists of Prostaglandin D2 Receptors
EP2300425A4 (en)	2008-06-24	2012-03-21	Panmira Pharmaceuticals Llc	PROSTAGLANDIN D2 RECEPTOR CYCLOALCANEÝBINDLUCK ANTAGONISTS
GB2465062B (en)	2008-11-06	2011-04-13	Amira Pharmaceuticals Inc	Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
PT2401269E (pt) *	2009-02-24	2014-03-11	Merck Canada Inc	Derivados de indol como antagonistas de recetor crth2
EP2480225A4 (en) *	2009-07-31	2013-05-01	Panmira Pharmaceuticals Llc	DERMAL FORMULATIONS FROM DP2 RECEPTOR ANTAGONISTS
AR080703A1 (es) *	2010-03-22	2012-05-02	Actelion Pharmaceuticals Ltd	Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma.
EP2457900A1 (en)	2010-11-25	2012-05-30	Almirall, S.A.	New pyrazole derivatives having CRTh2 antagonistic behaviour
PL2697223T3 (pl)	2011-04-14	2017-01-31	Actelion Pharmaceuticals Ltd.	Pochodne kwasu 7-(heteroaryloamino)-6,7,8,9-tetrahydropirydo[1,2-a]indolooctowego i ich zastosowanie jako modulatorów receptora prostaglandyny D2
CN104114169A (zh)	2011-12-16	2014-10-22	阿托佩斯治疗有限公司	用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物
HUE035738T2 (en) *	2013-05-28	2018-05-28	Astrazeneca Ab	Chemical compounds
EP3119779B1 (en)	2014-03-17	2018-07-11	Idorsia Pharmaceuticals Ltd	Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
ES2699379T3 (es)	2014-03-18	2019-02-11	Idorsia Pharmaceuticals Ltd	Derivados de ácido azaindol acético y su uso como moduladores del receptor de prostaglandina D2
CN116077665A (zh)	2014-05-08	2023-05-09	奇奥拉制药股份有限公司	用于治疗眼科疾病和障碍的化合物
US9907786B2 (en)	2014-10-21	2018-03-06	Ions Pharmaceutical S.À R.L.	Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US10092550B2 (en)	2014-10-21	2018-10-09	Ions Pharmaceutical S.À R.L.	Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
ES2991300T3 (es)	2015-02-13	2024-12-03	Inserm Institut Nat De La Sante Et De Larecherche Medicale	Antagonistas de PTGDR-1 y/o PTGDR-2 para prevenir y/o tratar lupus eritematoso sistémico
AU2016298263A1 (en)	2015-07-30	2018-03-01	The Trustees Of The University Of Pennsylvania	Single nucleotide polymorphic alleles of human DP-2 gene for detection of susceptibility to hair growth inhibition by PGD2
AU2016323262B2 (en)	2015-09-15	2020-11-19	Idorsia Pharmaceuticals Ltd	Crystalline forms
PL3761960T3 (pl)	2018-03-09	2024-04-15	Kiora Pharmaceuticals Gmbh	Preparat okulistyczny
TWI846704B (zh)	2018-06-21	2024-07-01	瑞士商赫孚孟拉羅股份公司	3-((1r,3r)-1-(2,6-二氟-4-((1-(3-氟丙基)氮雜環丁-3-基)胺基)苯基)-3-甲基-1,3,4,9-四氫-2h-吡啶并[3,4-b]吲哚-2-基)-2,2-二氟丙-1-醇之固體形式及用於製備包含經取代苯基或吡啶基部分之稠合三環化合物之製程，包括其使用方法
KR20210008223A (ko)	2019-07-11	2021-01-21	제이투에이치바이오텍 (주)	탈모증의 치료 또는 개선을 위한 화합물 및 이들의 용도
US12129265B2 (en)	2020-07-21	2024-10-29	Ankh Life Sciences Limited	Therapeutic agents and uses thereof
CN120917021A (zh) *	2023-03-15	2025-11-07	纽脑泰智有限公司	用于预防或治疗神经退行性疾病的包含新型吡啶并吲哚衍生物化合物作为活性成分的组合物

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4808608A (en)	1986-01-23	1989-02-28	Merck & Co., Inc.	Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
DE4118741A1 (de) *	1991-06-05	1992-12-10	Schering Ag	Neue hetaryloxy-(beta)-carboline, deren herstellung und verwendung in arzneimitteln
CA2171446C (en)	1993-09-09	2004-11-23	Donald James Kyle	Pseudo- and non-peptide bradykinin receptor antagonists
US5817756A (en)	1993-09-09	1998-10-06	Scios Inc.	Pseudo- and non-peptide bradykinin receptor antagonists
EA000987B1 (ru)	1995-06-21	2000-08-28	Сионоги Энд Ко., Лтд.	Бициклические аминопроизводные и содержащие их антагонисты pgd2
RU2140417C1 (ru) *	1995-10-17	1999-10-27	Институт физиологически активных веществ РАН	Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения
JP4120993B2 (ja)	1996-12-12	2008-07-16	塩野義製薬株式会社	ヘテロ環縮合ベンゼンカルボン酸アミド誘導体およびそれを含有するｐｇｄ２拮抗剤
DK0944614T3 (da)	1996-12-13	2003-01-13	Shionogi & Co	Benzothiophencarboxamidderivater og PGD2-antagonister, der omfatter dem
ATE295183T1 (de)	1998-06-03	2005-05-15	Shionogi & Co	Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten
DE1211513T1 (de)	1999-08-23	2002-11-14	Bml Inc., Tokio/Tokyo	Verfahren zum identifizieren von substanzen, die an prostaglandin d rezeptoren binden können
US20010047027A1 (en)	2000-04-12	2001-11-29	Marc Labelle	Prostaglandin D2 receptor antagonists
AU2001250206A1 (en)	2000-04-12	2001-10-30	Merck Frosst Canada Ltd	Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists
US7084136B2 (en)	2000-06-02	2006-08-01	Shionogi & Co., Ltd.	Drug composition antagonistic to both PGD2/TXA2 receptors
US6878522B2 (en)	2000-07-07	2005-04-12	Baiyong Li	Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
US7217725B2 (en)	2000-09-14	2007-05-15	Allergan, Inc.	Prostaglandin D2 antagonist
ATE287399T1 (de)	2000-10-17	2005-02-15	Shionogi & Co	Verfahren zur herstellung eines pgd2-antagonisten
WO2002036583A1 (en)	2000-11-01	2002-05-10	Shionogi & Co., Ltd.	Pgd2 receptor antagonistic pharmaceutical compositions
FR2821854B1 (fr)	2001-03-09	2004-07-16	Genoway	Cellules et animaux transgeniques d'etude de la polarisation de la reponse immune
DE60215000T2 (de)	2001-05-23	2007-08-09	Merck Frosst Canada & Co, Kirkland	Dihydropyrroloil[1,2-a]indol- und Tetrahydropyridol[1,2-a]indol-Derivate als Prostaglandin-D2-Rezeptor-Antagonisten
CA2454347A1 (en)	2001-07-18	2003-01-30	Merck Frosst Canada & Co./Merck Frosst Canada & Cie	Eosinophil prostaglandin d2 receptor assays
US20040197834A1 (en)	2001-07-20	2004-10-07	Francois Gervais	Method to increase expression of pgd2 receptors and assays for identifying modulators of prostaglandin d2 receptors
AR038136A1 (es)	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
SE0200411D0 (sv)	2002-02-05	2002-02-05	Astrazeneca Ab	Novel use
SE0200356D0 (sv)	2002-02-05	2002-02-05	Astrazeneca Ab	Novel use
AU2003231513A1 (en)	2002-05-16	2003-12-02	Shionogi And Co., Ltd.	Pgd2 receptor antagonist
US7534897B2 (en) *	2002-05-16	2009-05-19	Shionogi & Co., Ltd.	Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
GB2388540A (en)	2002-05-17	2003-11-19	Bayer Ag	New use of Ramatroban
SE0201635D0 (sv)	2002-05-30	2002-05-30	Astrazeneca Ab	Novel compounds
TW200307542A (en)	2002-05-30	2003-12-16	Astrazeneca Ab	Novel compounds
SE0202241D0 (sv)	2002-07-17	2002-07-17	Astrazeneca Ab	Novel Compounds
JP2006508077A (ja)	2002-10-04	2006-03-09	ミレニアム・ファーマシューティカルズ・インコーポレイテッド	炎症疾患を治療するためのｐｇｄ２レセプタアンタゴニスト
EP1413306A1 (en)	2002-10-21	2004-04-28	Warner-Lambert Company LLC	Tetrahydroquinoline derivatives as CRTH2 antagonists
DE60305724T2 (de)	2002-10-21	2006-11-09	Warner-Lambert Co. Llc	Tetrahydrochinolin-derivate als crth2 antagonisten
EP1558614B1 (en)	2002-10-30	2010-09-01	Merck Frosst Canada Ltd.	Pyridopyrrolizine and pyridoindolizine derivatives
CA2511214C (en)	2002-12-20	2012-12-18	Tularik, Inc.	Asthma and allergic inflammation modulators
EP1435356A1 (en)	2003-01-06	2004-07-07	Warner-Lambert Company LLC	Quinoline derivatives as CRTH2 antagonists
JPWO2004074240A1 (ja)	2003-02-20	2006-06-01	大正製薬株式会社	プロスタグランジン誘導体
WO2004078719A1 (ja)	2003-03-06	2004-09-16	Ono Pharmaceutical Co., Ltd.	インドール誘導体化合物およびその化合物を有効成分とする薬剤
SE0301010D0 (sv)	2003-04-07	2003-04-07	Astrazeneca Ab	Novel compounds
SE0301009D0 (sv)	2003-04-07	2003-04-07	Astrazeneca Ab	Novel compounds
DK1471057T3 (da)	2003-04-25	2006-05-15	Actimis Pharmaceuticals Inc	Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
US20070054951A1 (en)	2003-05-20	2007-03-08	Lianhai Li	Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists
SE0301569D0 (sv)	2003-05-27	2003-05-27	Astrazeneca Ab	Novel compounds
AU2004247285A1 (en)	2003-06-12	2004-12-23	Merck Frosst Canada Ltd	Cycloalkanepyrrolopyridines as DP receptor antagonists
WO2005007094A2 (en)	2003-07-09	2005-01-27	Tularik Inc.	Asthma and allergic inflammation modulators
SE0302232D0 (sv)	2003-08-18	2003-08-18	Astrazeneca Ab	Novel Compounds
SA04250253B1 (ar)	2003-08-21	2009-11-10	استرازينيكا ايه بي	احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
ES2345662T3 (es)	2004-03-11	2010-09-29	Actelion Pharmaceuticals Ltd.	Derivados de acido indol-1-il-acetico.
WO2006021418A1 (en)	2004-08-26	2006-03-02	Actelion Pharmaceuticals Ltd	2-sulfanyl-benzoimidazol-1-yl-acetic acid derivatives as crth2 antagonists
ATE518834T1 (de)	2004-12-27	2011-08-15	Actelion Pharmaceuticals Ltd	2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
JP5220013B2 (ja)	2006-08-07	2013-06-26	アクテリオンファーマシューティカルズリミテッド	（３−アミノ−１，２，３，４−テトラヒドロ−９ｈ−カルバゾール−９−イル）−酢酸誘導体

2005
- 2005-03-07 PT PT05715779T patent/PT1725553E/pt unknown
- 2005-03-07 BR BRPI0508540A patent/BRPI0508540B8/pt not_active IP Right Cessation
- 2005-03-07 DK DK05715779T patent/DK1725553T3/da active
- 2005-03-07 SI SI200530281T patent/SI1725553T1/sl unknown
- 2005-03-07 AU AU2005229356A patent/AU2005229356B2/en not_active Ceased
- 2005-03-07 DE DE602005006539T patent/DE602005006539D1/de active Active
- 2005-03-07 NZ NZ550365A patent/NZ550365A/en not_active IP Right Cessation
- 2005-03-07 US US10/598,777 patent/US7714132B2/en not_active Expired - Fee Related
- 2005-03-07 JP JP2007501238A patent/JP4051398B2/ja not_active Expired - Fee Related
- 2005-03-07 WO PCT/EP2005/002362 patent/WO2005095397A1/en not_active Ceased
- 2005-03-07 RU RU2006135651/04A patent/RU2387652C2/ru not_active IP Right Cessation
- 2005-03-07 PL PL05715779T patent/PL1725553T3/pl unknown
- 2005-03-07 CA CA2558509A patent/CA2558509C/en not_active Expired - Fee Related
- 2005-03-07 EP EP05715779A patent/EP1725553B1/en not_active Expired - Lifetime
- 2005-03-07 CN CN2005800076993A patent/CN1930162B/zh not_active Expired - Fee Related
- 2005-03-07 ES ES05715779T patent/ES2304010T3/es not_active Expired - Lifetime
- 2005-03-07 AT AT05715779T patent/ATE394399T1/de active
- 2005-03-07 KR KR1020067018133A patent/KR100808742B1/ko not_active Expired - Fee Related
- 2005-03-09 MY MYPI20050978A patent/MY143795A/en unknown
- 2005-03-11 TW TW094107583A patent/TWI369356B/zh not_active IP Right Cessation
- 2005-03-11 AR ARP050100957A patent/AR047928A1/es active IP Right Grant
2006
- 2006-09-07 IL IL177968A patent/IL177968A0/en active IP Right Grant
- 2006-10-10 NO NO20064584A patent/NO337996B1/no not_active IP Right Cessation
- 2006-10-10 ZA ZA200608446A patent/ZA200608446B/en unknown
2010
- 2010-03-16 US US12/724,946 patent/US20100234396A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN1930162A (zh)	2007-03-14
EP1725553B1 (en)	2008-05-07
CA2558509C (en)	2011-11-22
US7714132B2 (en)	2010-05-11
WO2005095397A1 (en)	2005-10-13
BRPI0508540A (pt)	2007-09-18
BRPI0508540A8 (pt)	2017-12-26
KR100808742B1 (ko)	2008-02-29
TWI369356B (en)	2012-08-01
AR047928A1 (es)	2006-03-01
CA2558509A1 (en)	2005-10-13
US20100234396A1 (en)	2010-09-16
PT1725553E (pt)	2008-07-16
ZA200608446B (en)	2008-06-25
IL177968A0 (en)	2006-12-31
MY143795A (en)	2011-07-15
TW200538434A (en)	2005-12-01
NZ550365A (en)	2010-09-30
BRPI0508540B1 (pt)	2019-04-02
BRPI0508540B8 (pt)	2021-05-25
DK1725553T3 (da)	2008-08-18
ES2304010T3 (es)	2008-09-01
KR20070029670A (ko)	2007-03-14
RU2006135651A (ru)	2008-04-20
DE602005006539D1 (de)	2008-06-19
JP2007526276A (ja)	2007-09-13
EP1725553A1 (en)	2006-11-29
US20070191416A1 (en)	2007-08-16
CN1930162B (zh)	2010-06-16
AU2005229356A1 (en)	2005-10-13
JP4051398B2 (ja)	2008-02-20
AU2005229356B2 (en)	2011-06-09
SI1725553T1 (sl)	2008-08-31
NO337996B1 (no)	2016-07-18
RU2387652C2 (ru)	2010-04-27
NO20064584L (no)	2006-10-10
ATE394399T1 (de)	2008-05-15

Publication	Publication Date	Title
TWI369356B (en)	2012-08-01	Tetrahydropyridoindole derivatives
IL180481A0 (en)	2007-06-03	Aryl-pyridine derivatives
IL180331A0 (en)	2007-07-04	3-carbamoyl - 2 - pyridone derivative
IL179736A0 (en)	2007-05-15	Pyrrazolo-pyrimidine derivatives
EP1878727A4 (en)	2013-11-13	2-AMINOQUINAZOLINE DERIVATIVES
IL192092A0 (en)	2008-12-29	Aryl-isoxazolo-4-yl-oxadiazole derivatives
ZA200707358B (en)	2009-08-26	1-benzylindole-2-carboxamide derivatives
HUS2000022I1 (hu)	2020-07-28	Tiglien-3-on származékok
IL182585A0 (en)	2007-07-24	Imidazo-benzodiazepine derivatives
IL183140A0 (en)	2007-09-20	Substituted benzoquinolizine derivatives
IL183142A0 (en)	2007-09-20	New pyridothienopyrimidine derivatives
IL192235A0 (en)	2009-02-11	Aryl-isoxazol-4-yl-imidazole derivatives
IL182739A0 (en)	2007-07-24	Acylatednonadepsipeptides used as lysobactin derivatives
AP2074A (en)	2009-12-14	New 4-benzylidene-piperidin derivatives
IL183141A0 (en)	2007-09-20	New pyridothienopyrimidine derivatives
IL191138A0 (en)	2008-12-29	Pyrazoloisoquinoline derivatives
GB0414272D0 (en)	2004-07-28	OsK1 derivatives
IL177204A0 (en)	2006-12-10	Novel 4-benzimidazol -2-ylpyridazin -3- one derivatives
IL179444A0 (en)	2007-05-15	4-phenyl-pyrimidine-2-carbonitrile derivatives
TWI346109B (en)	2011-08-01	4-amino-5-cyanopyrimidine derivatives
IL182001A0 (en)	2007-07-04	2-acylaminothiazole derivatives
GB0511410D0 (en)	2005-07-13	Benzotrizepinone derivatives
ZA200706577B (en)	2010-02-24	Dihydroimidazothiazole derivatives
GB0405905D0 (en)	2004-04-21	Azaquinazoline derivatives
GB0422397D0 (en)	2004-11-10	3-Cyano-Quinoline derivatives